Total: $710.16M | ||||
Company | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| | ||||
Aerogen Inc. (AEGN) |
Private sale of convertible preferred stock and warrants |
5S and 5W |
$15 |
Aerogen sold Series A-1 preferred stock initially convertible into 5M shares, and warrants to purchase up to 5M shares at $3.25 per share; Xmark Funds was lead investor; others were HealthCap, OrbiMed Advisors, Perceptive Life Sciences Fund Ltd. and SF Capital Partners; CIBC World Markets Corp. was placement agent in the financing, which was the first closing of a $32.7M round (3/24) |
Amylin Pharmaceuticals Inc. (AMLN) |
Private placement of convertible notes |
N/A |
$175 |
Amylin sold $175M of 2.5% convertible senior notes due 2011; the initial conversion price per share is $34.35, a 45% premium; purchasers have an option to buy another $25M of the notes (3/31) |
Australian Cancer Technology Ltd. (Australia; ASX:ACU) |
Private placement of stock |
9.52S |
A$3 (US$2.3) |
ACT sold the shares at A31.5 cents each, a 17% discount to the year-to-date average; Jaguar Advisory Services Pty. Ltd. underwrote the financing (3/16) |
Bioenvision Inc. (AMEX:BIV) |
Private placement of stock and warrants |
2S and 0.4W |
$12.8 |
The shares were priced at a 10% discount to the five-day average price, and the warrants are exercisable at $7.50 per share; existing Series A preferred shareholders have a 30 day right to buy shares under the same terms; SCO Securities LLC was placement agent (3/23) |
Corautus Genetics Inc. (AMEX:CAQ) |
Private placement of stock and warrants |
0.376S and 0.19W |
$2.25 |
The shares were priced at 88% of their value the previous day, and the two institutional investors got warrants exercisable at $8.375 per share; no placement fees were paid (3/19) |
CuraGen Corp. (CRGN) |
Sale of convertible subordinated notes |
N/A |
$10 |
Purchasers of $100M in notes in February exercised their option on another $10M in the 4% notes due 2011; they can be converted into common stock at $9.69 per share (3/16) |
Cytomedix Inc. (OTC BB: CYME) |
Private placement of preferred stock and warrants |
0.0028S and 2.8W |
$2.8 |
Cytomedix issued 280 Series C convertible preferred shares at $10,000 per share; each share is convertible into 10,000 common shares; the five-year warrants are exercisable at $1.50 each (3/29) |
Cytos Biotechnology AG (Switzerland; SWX:CYTN) |
Private placement of stock |
0.75S |
CHF30 (US$23.1) |
Cytos placed the shares with new and existing investors at a discount of about 20% to the prior day's close; global coordinator Deutsche Bank Group has an option on 100,000 additional shares (3/25) |
Discovery Laboratories Inc. (DSCO) |
Underwritten offering |
2.2S |
$24.2M |
Discovery Labs sold the shares from a shelf registration statement at $11 per share; Bear, Stearns & Co. Inc. was lead manager (3/30) |
DOR BioPharma Inc. (AMEX:DOR) |
Private placement of stock and warrants |
4.11S and 1.65W |
$3.25 |
DOR sold the shares to instutional investors, which also got five-year warrants exercisable at 87 cents per share (3/4) |
DOV Pharmaceutical Inc. (DOVP) |
Private placement of stock |
0.667S |
$10 |
DOV sold the shares at $15 each to undisclosed institutional investors (3/29) |
Draxis Health Inc. (Canada; DRAX) |
Bought-deal sale of units |
3.053U |
C$20 (US$15.3) |
The units, priced at C$6.55 each, consist of one common share and one-half of one share warrant; each two-year whole warrant entitles the holder to acquire one share at C$8.50; underwriters have an option to purchase another 458,016 units (3/31) |
Genesis Bioventures Inc. (AMEX:GBI) |
Private placement of securities |
ND |
$2 |
Genesis raised the money in conjunction with its proposed acquisition of Corgenix Medical Corp., which will be advanced $0.5M from the proceeds; terms of the financing were not disclosed; Sterling Financial Investment Group was placement agent (3/16) |
GenoMed Inc. (OTC BB:GMED) |
Private equity deal |
N/A |
$0.5 |
Pierpoint Investissements SA agreed to invest at least $500,000 and up to $2M in GenoMed for the next 10 years in return for restricted shares priced at a modest discount; Pierpoint will keep active warrants for another 35M shares that could be converted only if the share price reaches $1 (3/3) |
GTC Biotherapeutics Inc. (GTCB) |
Private placement of stock |
6.4S |
$15 |
GTC placed the stock covered under a shelf registration statement with institutional investors at $2.35 per share; lead SG Cowen Securities Corp. and Rodman & Renshaw LLC were placement agents (3/16) |
Helix BioMedix Inc. (OTC BB:HXBM) |
Private placement of stock and warrants |
0.55S and 0.193W |
$1.1 |
Helix said the money raised represented what was expected to be the first closing in the financing; terms on the warrants were not disclosed (3/22) |
Incyte Corp. (INCY) |
Private placement of convertible notes |
N/A |
$50 |
Purchasers of $200M of notes in February bought another $50M of the 3.5% notes due 2011; the notes have an initial conversion price of about $11.22 per share (3/8) |
InSite Vision Inc. (AMEX:ISV) |
Private placement of units |
0.194U |
$2 |
Each unit consists of 20,000 shares of common stock at $0.50 per share and 5,000 Class A and 5,000 Class B warrants, with each warrant enabling the holder to purchase common shares at $0.75 each; the deal is expected to be the initial closing in a $16.5M financing; Paramount BioCapital Inc. was placement agent (3/29) |
Integrated Pharmaceuticals Inc. (OTC BB:INTP) |
Privateplacement of stock and warrants |
4.2S and 2.1W |
$4.2 |
The shares were priced at $1 each and the warrants are exercisable through 2006 at $2.50 per share; one investor also received a 90-day option to buy up to $1.2M in common stock (3/11) |
La Jolla Pharmaceutical Co. (LJPC) |
Underwritten stock sale |
1.3S |
$4.1 |
Pacific Growth Equities LLC exercised its option to purchase 1.3M additional shares from a financing that priced in February; gross proceeds of the sale totaled about $31.5M (3/5) |
Large Scale Biology Corp. (LSBC) |
Private placement of stock and warrants |
5.2S and 1.3W |
$8.2 |
Large Scale sold the shares at about $1.58 each; the five-year warrants were priced at a premium of 20%; The Shemano Group Inc. was placement agent (3/10) |
Lynx Therapeutics Inc. (LYNX) |
Private placement of stock and warrants |
0.788S and 0.181W |
$4 |
Lynx sold the shares to institutional investors at $5.10 per share; the warrants are exercisable at $6.25 per share (3/10) |
MacroChem Corp. (MCHM) |
Private placement of stock and warrants |
5.4S and 1.08W |
$7.29 |
MacroChem sold about 5.4M shares at $1.35 per share to institutional investors, which also got five- year warrants to purchase 1.08M shares at $2.09 per share; JMP Securities LLC was placement agent (3/10) |
Matritech Inc. (AMEX:MZT) |
Private placement of stock and warrants |
4.86S and 1.65W |
$6.56 |
Matritech sold the shares at $1.35 each; the war- rants are exercisable at $2 per share; Rodman & Renshaw LLC was placement agent and got 434,475 of the warrants that were issued (3/19) |
MediGene AG (Germany; FSE:MDG) |
Private placement of stock |
1.1S |
€7.5 (US$9.2) |
MediGene sold the shares at €6.80 each to insti- tutional investors in the first of three steps to raise €16M; Techno Management Ventures participated in the deal (3/11) |
MGI Pharma Inc. (MOGN) |
Private placement of convertible notes |
N/A |
$35 |
Placement agents in a February sale of 2.25% notes exercised their option on another $35M in notes, which have an initial conversion price of $62.92 per share; the financing now totals $260M (3/2) |
Microbix Biosystems Inc. (Canada; TSE:MBX) |
Convertible debenture sale |
N/A |
C$0.5 (US$0.38) |
Microbix entered a deal to sell an 8% convertible debenture to an existing shareholder; the note is convertible into common stock at C$0.90 per share for eight years (3/22) |
MicroIslet Inc. (OTC BB:MIIS) |
Private placement of stock and warrants |
9.8S and 4.9W |
$12.8 |
The shares were sold at about $1.31 each; warrant terms were not disclosed; Burnham Hill Partners and Duncan Capital were placement agents (3/10) |
Miraculins Inc. (Canada; VSE:MOM) |
Private placements of units |
4U |
C$2 (US$1.53) |
The units, priced at C$0.50 each, consist of one common share and one-half of a warrant; each whole warrant is exercisable at C$0.75 for six months; Bieber Securities Inc. was agent for the financing (3/26) |
Nanogen Inc. (NGEN) |
Private placement of stock |
4.25S |
$33.75 |
Nanogen sold the shares from a shelf registration statement to institutional investors at $7.94 each; Seven Hills Partners LLC was placement agent (3/5) |
NaPro Biotherapeutics Inc. (NPRO) |
Private placement of stock |
2S |
$5.2 |
NaPro sold the shares from a shelf registration statement to two institutional investors (3/26) |
Neurobiological Technologies Inc. (NTII) |
Private placement of stock and warrants |
3.88S and 0.582W |
$19.4 |
NTI sold the shares at $5 each, and the warrants are exercisable at $6.73 per share; Merriman Curhan Ford & Co. was placement agent (3/2) |
Neurogen Corp. (NRGN) |
Private placement of stock |
14.29S |
$100 |
Neurogen sold the shares at $7 each; Warburg Pincus LLC and Baker Brothers Investments were lead investors (3/19) |
Oncolytics Biotech Inc. (Canada; ONCY) |
Private placement of stock and warrants |
1.077S and 0.539W |
C$6.73 (US$5.1) |
A European institutional investor purchased the shares and warrants, which are exercisable at C$7.75 per share (3/24) |
Pheromone Sciences Corp. (Canada; TSE:PHS) |
Private placement of convertible debentures |
N/A |
C$0.33 (US$0.25) |
Each C$1 principal amount is convertible into 10 shares and 10 warrants; each warrant allows the holder to purchase one share at C$0.10 by Feb. 4, 2005 (3/4) |
Point Therapeutics Inc. (OTC BB:POTP) |
Private placement of stock and warrants |
3S and 0.9W |
$13.5 |
PTI sold the shares at $4.50 each and the five-year warrants are exercisable at $6.25 per share; RBC Capital Markets and Paramount BioCapital Inc. were placement agents (3/25) |
SuperGen Inc. (SUPG) |
Private placement of stock and warrants |
4.86S and 0.729W |
$34 |
SuperGen sold the shares at $7 each to institutional investors; the warrants are exercisable at $10 per share; Rodman & Renshaw was placement agent (3/5) |
Tissera Inc. (Israel; OTC BB:TSSR) |
Private equity placement |
ND |
$5.5 |
Details of the financing with individual and institutional investors were not disclosed (3/22) |
Titan Pharmaceuticals Inc. (AMEX:TTN) |
Private placement of stock |
3S |
$15 |
Titan sold the shares from a shelf registration at $5 each to institutional and an individual investor; Rodman & Renshaw LLC was placement agent (3/26) |
Vical Inc. (VICL) |
Registered direct offering |
3.4S |
$18.6 |
Vical is selling the shares from a shelf registration at $5.50 each to institutional investors; SG Cowen Securities Corp. was placement agent (3/23) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currency conversions reflect rates at the time of the deal. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
